Importantly, we also identified two potential therapeutic targets, ANO1 and SQLE, for patients with upregulated TAZ-AXL-CTGF expression; downregulation of either of these two genes may greatly improve the survival of TAZ-AXL-CTGF-high colon cancer patients. The gene discussed is CCN2; the disease is colonic neoplasm.